UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 6,829 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 3.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 218,544 shares of the company's stock after selling 6,829 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.36% of Rhythm Pharmaceuticals worth $12,234,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Janus Henderson Group PLC lifted its holdings in Rhythm Pharmaceuticals by 103.9% in the 4th quarter. Janus Henderson Group PLC now owns 1,219,554 shares of the company's stock worth $68,309,000 after purchasing an additional 621,432 shares in the last quarter. Marshall Wace LLP raised its holdings in shares of Rhythm Pharmaceuticals by 70.4% in the fourth quarter. Marshall Wace LLP now owns 692,803 shares of the company's stock valued at $38,783,000 after acquiring an additional 286,188 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Rhythm Pharmaceuticals by 24.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 685,152 shares of the company's stock valued at $38,355,000 after acquiring an additional 134,622 shares in the last quarter. Hood River Capital Management LLC raised its holdings in shares of Rhythm Pharmaceuticals by 4.7% in the fourth quarter. Hood River Capital Management LLC now owns 643,691 shares of the company's stock valued at $36,034,000 after acquiring an additional 29,093 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Rhythm Pharmaceuticals by 9.4% in the fourth quarter. Northern Trust Corp now owns 545,314 shares of the company's stock valued at $30,527,000 after purchasing an additional 46,848 shares during the last quarter.

Rhythm Pharmaceuticals Stock Performance

Shares of Rhythm Pharmaceuticals stock traded up $1.75 on Monday, reaching $63.08. 168,464 shares of the company were exchanged, compared to its average volume of 554,380. The company's 50-day moving average is $59.55 and its two-hundred day moving average is $57.54. The firm has a market cap of $4.01 billion, a price-to-earnings ratio of -14.59 and a beta of 2.36. Rhythm Pharmaceuticals, Inc. has a 1-year low of $36.27 and a 1-year high of $68.58.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.12). Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The business had revenue of $37.72 million during the quarter, compared to analyst estimates of $40.43 million. During the same quarter in the prior year, the business earned ($2.35) earnings per share. The firm's revenue was up 25.9% compared to the same quarter last year. As a group, sell-side analysts forecast that Rhythm Pharmaceuticals, Inc. will post -4.32 earnings per share for the current year.

Insider Buying and Selling at Rhythm Pharmaceuticals

In related news, EVP Yann Mazabraud sold 75,000 shares of the stock in a transaction on Friday, March 14th. The stock was sold at an average price of $51.48, for a total transaction of $3,861,000.00. Following the completion of the sale, the executive vice president now directly owns 40,370 shares in the company, valued at approximately $2,078,247.60. This trade represents a 65.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Pamela J. Cramer sold 7,031 shares of Rhythm Pharmaceuticals stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $65.09, for a total value of $457,647.79. Following the sale, the insider now directly owns 19,209 shares in the company, valued at approximately $1,250,313.81. This trade represents a 26.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 127,630 shares of company stock valued at $7,107,346. 6.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Stifel Nicolaus lifted their target price on Rhythm Pharmaceuticals from $78.00 to $94.00 and gave the company a "buy" rating in a research note on Thursday. Wells Fargo & Company boosted their price target on Rhythm Pharmaceuticals from $80.00 to $91.00 and gave the stock an "overweight" rating in a research note on Monday, April 7th. Canaccord Genuity Group upped their target price on Rhythm Pharmaceuticals from $81.00 to $92.00 and gave the company a "buy" rating in a research report on Tuesday, April 8th. HC Wainwright reiterated a "buy" rating and issued a $80.00 target price (up previously from $70.00) on shares of Rhythm Pharmaceuticals in a research report on Tuesday, April 8th. Finally, Bank of America upgraded Rhythm Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $63.00 price objective on the stock in a research report on Monday, April 7th. Thirteen analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $76.62.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.